Repair of Severe Tricuspid Regurgitation in a Neonate With Intrauterine Tricuspid Valve Chordae Tendinae Rupture.

World J Pediatr Congenit Heart SurgJan 29, 2026 (epub)
Case ReportCardiothoracic SurgeryPediatrics

Yi-Chia Wang, Heng-Wen Chou, Szu-Yen Hu et al.

✦ AI-curated · Sources linked

Case in brief

A neonate presented with severe tricuspid regurgitation (TR) and hydrops fetalis associated with tricuspid valve chordae tendinae rupture that had occurred in utero. The infant underwent rescue tricuspid valve repair using artificial chordae, leaflet approximation, and annular reduction. The repair was successful.

What made this case unusual

The severe neonatal TR and hydrops were linked to intrauterine rupture of the tricuspid valve chordae tendinae, an uncommon finding in neonates.

Diagnostic / clinical pearl

In a neonate with severe TR and hydrops fetalis, intrauterine tricuspid chordal rupture is a possible structural explanation.

Source

PubMed · PMID 41610212

Published in World J Pediatr Congenit Heart Surg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiothoracic Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.